Zydus Receives Final Approval From The USFDA For Balsalazide Disodium Capsules

Zydus Receives Final Approval From The USFDA For Balsalazide Disodium Capsules

The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.

FPJ Web DeskUpdated: Saturday, June 10, 2023, 02:50 PM IST
article-image
Zydus Receives Final Approval From The USFDA For Balsalazide Disodium Capsules | Image: Zydus (Representative)

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Balsalazide Disodium Capsules USP, 750 mg, the company announced through an exchange filing.

The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.

Balsalazide Disodium Capsules USP, 750 mg had annual sales of USD 29 mn in the United States (IQVIA MAT April 2023).

Balsalazide Disodium is used to treat bowel diseases like ulcerative colitis. It helps reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain. Balsalazide belongs to a class of drugs known as aminosalicylates and works by reducing swelling in the colon. (India).

The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

RECENT STORIES

Ahmedabad Plane Crash: Air India Offers ₹25 Lakh Immediate Relief To Victims' Families In Addition...

Ahmedabad Plane Crash: Air India Offers ₹25 Lakh Immediate Relief To Victims' Families In Addition...

iOS 26: New Features Announced For iPhones At WWDC 2025

iOS 26: New Features Announced For iPhones At WWDC 2025

RBI Likely To Ease Interest Rates, Revises Inflation Target For FY26 To 3.7%; Average Inflation For...

RBI Likely To Ease Interest Rates, Revises Inflation Target For FY26 To 3.7%; Average Inflation For...

Elon Musk Recommends Deorbiting International Space Station Within 2 Years

Elon Musk Recommends Deorbiting International Space Station Within 2 Years

SpiceJet's Revenue From Operations Falls 16% To ₹1,446.37 Crore In Q4 FY25

SpiceJet's Revenue From Operations Falls 16% To ₹1,446.37 Crore In Q4 FY25